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ABSTRACT 24 
Background: Low serum 25-hydroxyvitamin D [25(OH)D] levels have been associated with 25 
higher risk of many diseases that affect mortality, including cardiovascular disease and 26 
cancer. The inverse association between serum 25(OH)D and mortality may be modified by 27 
excess circulating vitamin A, due to interactions of vitamin A at the level of the vitamin D 28 
nuclear receptor. In this prospective cohort study, we investigated whether the association 29 
of 25(OH)D with all-cause, cancer and cardiovascular disease mortality was modified by 30 
circulating vitamin A or preformed vitamin A intake from supplements. 31 
Methods: We analyzed 15,998 adults in the Third National Health and Nutrition 32 
Examination Survey (NHANES III), 1988-1994. Mortality data for all-cause (n=3890), 33 
cancer (n=844) and CVD mortality (n=1715) was assessed through December 2006. Serum 34 
25(OH)D was measured using a radio-immunoassay kit, vitamin A biomarkers were 35 
measured by HPLC, and information on supplement use was obtained by self-report. 36 
Multivariable hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were 37 
estimated by proportional hazards regression. 38 
Results: Serum 25(OH)D was significantly inversely associated with all-cause mortality 39 
(HR: 0.93, 95% CI 0.89, 0.97, per 10 ng/mL increase), and also with cardiovascular disease 40 
(CVD) mortality and mortality due to non-cancer/non-cardiovascular causes, but not with 41 
cancer mortality. The observed inverse associations remained statistically significant only 42 
among participants with serum retinyl esters <͹.Ͳ μg/dL. High intake (>5000IU/day) of 43 
preformed vitamin A from supplements attenuated the inverse association of 25(OH)D with 44 
overall mortality. The observed interactions were not statistically significant.  45 
 3 
Conclusions: 25(OH)D was inversely associated with overall mortality, CVD mortality and 46 
mortality due to non-cancer/non-CVD causes, but not with cancer mortality. A possible 47 
interaction between vitamin A exposure and 25(OH)D concentration appears to be 48 
associated with an attenuation of the inverse association between risk of death and quartile 49 
of 25(OH)D concentration. 50 
  51 
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INTRODUCTION 52 
Vitamin D is a fat-soluble steroid molecule that plays a pivotal role in the maintenance of 53 
musculoskeletal health. For several years, however, vitamin D is emerging as a critical 54 
regulator of the pathogenetic process of a number of non-skeletal diseases such as 55 
cardiovascular [1] and autoimmune disorders [2,3], infections [4,5] and several types of 56 
cancers [6,7], indicating a possible pleiotropic effect across extraskeletal systems. 57 
Accordingly, it was suggested that low levels of vitamin D may increase the risk of death 58 
due to the wide ranging anti-inflammatory and immune modulating effects [8,9]. A recently 59 
published meta-analysis of observational and trial data relating vitamin D to the risk of all-60 
cause and cause-specific mortality found inverse associations of circulating 25-61 
hydroxyvitamin D [25(OH)D] concentration with risks of death due to cardiovascular 62 
disease, cancer, and non-vascular/non-cancer causes [10]. Suggested biological functions in 63 
the suspected causal pathway include immune-modulatory properties, induction of cell 64 
differentiation, inhibition of angiogenesis and cell proliferation, stimulation of insulin 65 
production, and inhibition of rennin production [11,12,7,13-15]. Given the high prevalence 66 
of vitamin D deficiency worldwide, this issue is becoming of paramount importance [16]. 67 
Most of the biologic activities of vitamin D are mediated by its binding to a high-affinity 68 
nuclear receptor (VDR) that acts as a ligand-activated transcription factor. A crucial step in 69 
the control of gene transcription by VDR involves heterodimerization with the retinoid X 70 
receptor (RXR), in order that high affinity binding of the heterodimer (RXR-VDR) to specific 71 
DNA sites – the vitamin D response elements (VDREs) – can occur [17]. However, 72 
excessively high concentrations of 9-cis-retinoic acid, an active metabolite of vitamin A and 73 
the ligand of RXR, can lead to the formation of RXR-RXR homodimers instead of 74 
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heterodimers with VDR. If this highly regulated heterodimerisation process is interrupted, 75 
vitamin D cannot exert its important transcriptional effects in the human body [18]. Recent 76 
data from epidemiological studies suggest that the association between 25(OH)D and 77 
cancer incidence or mortality is modified by vitamin A, such that excess circulating vitamin 78 
A may attenuate a beneficial association [19-22]. Studies on the association of 25(OH)D 79 
with mortality other than cancer mortality so far have not considered a potential vitamin D-80 
vitamin A interaction effect. We tested the hypothesis that inverse associations of serum 81 
25(OH)D with all-cause, cancer, CVD and non-cancer/non-CVD mortality are modified by 82 
circulating levels of vitamin A in a prospective cohort of healthy US adults (NHANES III; 83 
1988–1994). 84 
 85 
SUBJECTS AND METHODS 86 
Study population 87 
NHANES is a data collection program designed to assess the health and nutritional status of 88 
the civilian, non-institutionalized population in the United States. The third NHANES study 89 
was conducted by the National Center for Health Statistics (NCHS) between 1988 and 1994 90 
using a stratified, multistage probability design. In order to provide reliable estimates for 91 
specific subgroups of the US population, young children, older persons (aged 65 or older), 92 
black persons, and Mexican Americans were oversampled. NHANES III collected household 93 
interview data including demographics and data on health and nutrition for 33,994 (85.6%) 94 
of the 39,695 invited participants. Subsequent physical and laboratory examinations in 95 
mobile examination centers (MEC) or at home visits were conducted for 30,882 (77.8%) 96 
subjects. The NCHS Institutional Review Board approved all procedures, and all subjects 97 
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were provided a written informed consent sheet. Detailed methods for the NHANES III 98 
baseline data collection, including sampling, in-house interview, physical examination, 99 
laboratory measurements, mortality linkage, ethics approval, and informed consent have 100 
been described elsewhere [23]. All analyses in this report are based on NHANES data 101 
extracted from the publicly available NHANES website. 102 
Our analysis was restricted to the 20,024 adults, defined as 17 years or older in NHANES III. 103 
We excluded those who did not complete both the interview and the subsequent MEC 104 
examination including a blood draw (n=1875), women who were pregnant at baseline 105 
(n=280), individuals without reported serum 25(OH)D measurement (n=1159) and 106 
participants without complete information on the study variables (n=712), resulting in a 107 
cohort of 15,998 individuals. 108 
 109 
Mortality follow-up 110 
The NHANES III linked mortality file provides mortality follow-up data from the date of 111 
survey participation (1988-1994) through December 31, 2006. All participants aged 17 112 
years or older at baseline were eligible for mortality follow-up. Vital status was assessed 113 
based primarily upon the results from a probabilistic match between NHANES III and 114 
National Death Index (NDI) death certificate records [24]. The follow-up period was 115 
calculated as the time from examination to either a mortal event or censoring date. 116 
Underlying cause of death was coded using the 9th revision of the International Statistical 117 
Classification of Diseases, Injuries, and Causes of Death (ICD-9) for deaths occurring 118 
between 1988 and 1998, and the 10th ICD revision (ICD-10) for deaths occurring between 119 
1999 and 2006. All death before 1999 were recoded by the NCHS to ICD-10 codes for 120 
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comparability. Cardiovascular disease mortality was defined as ICD-10 codes I00–I99, 121 
corresponding to the ICD-9 codes 390–434 and 436–459 and cancer mortality as ICD-10 122 
codes C00–C34, C37–C41, C43–C49, C50–C52, C54–C65, C67–C80, C82–C85, C88, C90–C95 123 
and C97, corresponding to the ICD-9 codes 140–239. Non-cancer/non-CVD mortality 124 
included all death with known underlying causes, except CVD and cancer deaths. All-cause 125 
mortality included all specified causes of death as well as cases with unknown cause. During 126 
the median 14.5 years of follow-up, there were 3890 (24%) deaths in our analytical cohort, 127 
including 1715 CVD-related deaths and 844 cancer-related deaths. 128 
 129 
Covariate assessment 130 
Information on age, sex, race/ethnicity, and socioeconomic status was obtained by self-131 
report from the household interview. Race/ethnicity was reported as non-Hispanic white, 132 
non-Hispanic black, Mexican-American (defined as persons of Mexican origin living in the 133 
United States), and others (including multiracial). Age was defined as the age in years at 134 
time of recruitment. Socioeconomic status was assessed using the poverty income ratio, a 135 
calculated variable based on family income and family size, and self-reported years of 136 
schooling (less, equal, more than high school). Information on alcohol consumption was 137 
divided into 3 categories (none, 1–8, 9+ times/month) and smoking history was classified 138 
according to current (1-20 cigarettes/day, >20 cigarettes/day), former or never smokers. 139 
The level of physical activity was categorized into none, 1-3, 4+ times of moderate physical 140 
activity per week. In women, hormone replacement therapy was also assessed. History of 141 
obstructive pulmonary disease (defined as any positive response to one of the diagnoses of 142 
asthma, emphysema or chronic bronchitis), as well as myocardial infarction, stroke, heart 143 
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failure, and cancer were assessed through self-reporting. Intake and type (product label) of 144 
mineral and vitamin supplements were recorded from the 30-day supplement interview. As 145 
there is no evidence that pro-vitamin A properties arising from dietary intakes of 146 
carotenoids contribute to vitamin A-related toxicity [25,26], the present study only 147 
considered intake of supplements containing preformed vitamin A in the form of retinol 148 
and its esters. Supplement use was divided into quartiles based on information on 149 
frequency and quantity (units each time) of consumption in the past month. 150 
From physical examination data, height and weight were used to calculate the body mass 151 
index (BMI) as kg/m2. Hypertension, diabetes mellitus and hypercholesterolemia were 152 defined by history/physicianǯs diagnosis or medication use. Fasting blood samples collected 153 
during examination were centrifuged, aliquoted, and frozen to -70°C before transport on 154 
dry ice to central laboratories for analysis. Blood collection in mobile unites was performed 155 
in two seasonal groups based generally on latitude, with southern collections undertaken 156 
during the winter months (November to March), and northern collections during the 157 
summer months (April to October). To account for variability of latitude and season, we 158 
divided our sample into two groups: winter/ lower latitude and summer/higher latitude. 159 
Serum 25(OH)D was measured using a radio-immunoassay kit (Diasorin, Stillwater, MN). 160 
Serum levels of retinol and retinyl esters (that is, the sum of retinyl linoleate, retinyl oleate, 161 
retinyl palmitate and retinyl stearate) were assayed by isocratic high-performance liquid 162 
chromatography with detection at three different wavelengths (Waters, Milford, MA). 163 
 164 
Statistical Analysis 165 
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All analyses were performed using STATA statistical software version 13 (StataCorp. 2013, 166 
College Station, Texas, USA). In order to account for the complex survey design of NHANES 167 
III all analyses were weighted by using the ǮǮsurveyǯǯ command, with the ǲsubpopǳ option to 168 
subset data. A 2-sided P value of 0.05 was the criterion for statistical significance. 169 
Continuous variables are expressed as mean +/- standard deviation (SD), categorical 170 
variables are presented as proportions. Cox proportional hazard regression models were 171 
used to examine the association between 25(OH)D concentrations and mortality, whereby 172 
multivariable–adjusted hazard ratios (HR) and 95 % confidence intervals (CI) were 173 
estimated for total and cause-specific mortality. Serum 25(OH)D concentration was 174 
modeled continuously (per 10 ng/mL) and in quartiles based on the unweighted 175 
distribution in the cohort. For all participants, time at entry was the date of physical 176 
examination. Time at exit was either date of death or date of censoring, whichever came 177 
first. Covariates included in the multivariable models were selected a priori. The primary 178 
analysis focused on the association between baseline serum 25(OH)D concentration and all-179 
cause, cancer, CVD, and non-cancer/non-CVD mortality during follow-up. Three different 180 
multivariable models were used, specified a priori, to test for the independent effect of 181 
serum 25(OH)D on mortality. The first model adjusted for age, sex, race/ethnicity and 182 
season. Building on the first model, the second model further adjusted for lifestyle and 183 
socioeconomic factors, including BMI, smoking status, alcohol consumption, physical 184 
activity, and hormone replacement therapy in women as well as poverty income ratio and 185 
education level. The third model added potential mediators in the suspected causal 186 
pathway to help explain the observed associations. This model also included hypertension, 187 
diabetes mellitus, hypercholesterolemia, obstructive pulmonary disease, and history of 188 
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myocardial infarction, stroke, and cancer. To examine a potential modifying effect of 189 
vitamin A on main effects of serum 25(OH)D we ran stratified analyses by excess circulating 190 
vitamin A and preformed vitamin A supplement use. Currently, there is no well-accepted, 191 
non-invasive physiological measure of vitamin A excess. Serum retinol is tightly regulated 192 
by liver storage and by the production of retinol-binding protein, and is likely a better 193 
biomarker of vitamin A deficiency rather than excess [27]. While serum retinol may only 194 
slightly be elevated when vitamin A intake is excessive, serum retinyl esters are markedly 195 
increased [28]. Therefore, fasting retinyl ester levels have been used as a marker of possible 196 
vitamin A toxicity or hypervitaminosis A [29,30]. Under normal conditions retinyl esters 197 
account for less than 5% of total serum vitamin A [30] and concentrations η͹.Ͳ μg/dL have 198 
been interpreted as marker of potential toxicity [27]. In our study, excess circulating 199 
vitamin A was therefore defined as serum retinyl esters η͹ μg/dL. Data were also stratified 200 
by quartiles of serum retinol and preformed vitamin A intake from supplements. Since a 201 
definitive cut-off value to indicate excess vitamin A is lacking for both markers, the 75th 202 
percentile was used as threshold in the analyses. Effect modification was assessed on a 203 
multiplicative scale by using the Wald test to compare adjusted Cox models with and 204 
without an interaction term of serum 25(OH)D and the vitamin A stratification variable. To 205 
at least partially preclude reverse causation, we conducted additional analyses by excluding 206 
cases during the first 5 years of follow-up. Restricted cubic spline models were used to 207 
provide evidence of non-linear relations between 25(OH)D and mortality. 208 
 209 
RESULTS 210 
 11 
Table 1 summarizes demographic characteristics and confounding variables of the 211 
weighted NHANES III sample according to serum 25(OH)D quartiles. Median 25(OH)D 212 
concentration was 28.3 ng/mL (weighted sample), mean age at baseline was 43.4 years. 213 
Individuals with low 25(OH)D concentrations were older, less physically active, and more 214 
often female. Blacks and Mexican Americans were overrepresented in the lowest quartile of 215 
25(OH)D concentration. Higher 25(OH)D concentration was associated with a higher 216 
educational level, higher income, and lower prevalence of diabetes, hypertension, COPD, as 217 
well as history of stroke and myocardial infarction.  218 
During the 14.5 years of follow-up, 3890 (24.3 %) of the 15,998 study participants died. Of 219 
these, 844 (21.7 %) deaths were related to cancer and 1715 (44.1 %) to CVD. A significant 220 
association of serum 25(OH)D with all-cause mortality was observed when adjusting for 221 
age, sex, race/ethnicity and season (HR: 0.89; 95% CI: 0.85, 0.94 per 10 ng/mL increase in 222 
25(OH)D; Table 2). The inverse association remained statistically significant even after 223 
controlling for potential confounders and intermediate variables (HR: 0.93; 95 % CI: 0.89, 224 
0.97 per 10 ng/mL increase in 25(OH)D). A similar pattern was observed in the categorical 225 
model, where HRs tended to decrease with increasing quartiles of 25(OH)D. Comparing 226 individuals with a high ʹͷȋO(ȌD concentration of ηͶͲ ng/mL ȋͳͲͲ nmol/LȌ to those with 227 
concentrations <16 ng/mL (25 nmol/L), we observed a HR of 0.70 (95% CI: 0.50, 0.83). 228 
Excluding the first five years of follow-up did not materially affect the observed associations 229 
(data not shown). Results of the restricted cubic spline models did not indicate a non-linear 230 
association between serum 25(OH)D and mortality (P-value >0.05; results not shown). 231 
The inverse association between 25(OH)D and all-cause mortality remained statistically 232 
significant among participants with serum retinyl ester concentrations <͹.Ͳ μg/dL ȋ(R: 233 
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0.92; 95% CI 0.88, 0.97 per 10 ng/mL increase in 25(OH)D), but not among those with 234 
serum retinyl esters η͹.Ͳ μg/dL ȋ(R: Ͳ.ͻ͹, ͻͷ% C) Ͳ.ͺͷ, ͳ.Ͳͻ; P-interaction = 0.59). 235 
Similarly, in the categorical model a statistically significant inverse association of serum 236 
25(OH)D with all-cause mortality was observed for serum retinyl esters <͹.Ͳ μg/dL (Figure 237 
1). When data were stratified by preformed vitamin A supplement use, effect estimates 238 
were generally lower among participants taking supplements. However, looking at vitamin 239 
A supplement use in more detail, the potential protective effect of 25(OH)D on overall 240 
mortality held for individuals taking supplements containing preformed vitamin A at 241 
amounts ζ5000 IU (HR: 0.87,95% CI 0.77, 0.97 per 10 ng/mL increase in 25(OH)D), but not 242 
for those taking high amounts (>5000 IU) of preformed vitamin A from supplements (HR: 243 
1.01, 95% CI 0.72, 1.43; P-interaction = 0.53). However, these results should be interpreted 244 
with caution due to the low case numbers in the subgroups. When stratifying by serum 245 
retinol, HR tended to decrease with increasing quartiles of 25(OH)D concentrations in both 246 
strata, with the risk reduction being more pronounced at high concentrations (>69 μg/dL) 247 
of serum retinol (HR: 0.64, 95% CI 0.48, 0.86 for serum retinol >69 μg/dL and HR: 0.82, 248 
95% CI 0.71, 0.96 for serum retinol ζ ͸ͻ μg/dL; top vs. bottom quartile; P-interaction = 249 
0.16). Generally, the strength of associations was similar when analyses were stratified by 250 
sex (Supplementary Table 1).  251 
Overall, there was no significant association between serum 25(OH)D and total cancer 252 
mortality (Supplementary Table 2). Similar to associations seen with all-cause mortality, 253 
lower 25(OH)D was associated with increased CVD mortality (HR = 0.79, 95% CI 0.67, 0.94; 254 
top vs. bottom quartile, model 3; Supplementary Table 2). At serum retinyl ester 255 
concentrations <7 μg/dL and serum retinol concentrations > ͸ͻ μg/dL, 25(OH)D 256 
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maintained its inverse association with CVD mortality (HR: 0.76, 95% CI 0.61, 0.95 and HR: 257 
0.62, 95% CI 0.44, 0.89, respectively; top vs. bottom quartile). Mortality due to non-258 
cancer/non-CVD causes was significantly inversely associated with 25(OH)D in the 259 
multivariable-adjusted model (HR: 0.89, 95% CI 0.82, 0.97 per 10 ng/mL increase in 260 
25(OH)D). Lower serum retinyl esters as well as preformed vitamin A supplement use were 261 
associated with lower mortality (HR: 0.87, 95% CI 0.78, 0.96 and HR: 0.79, 95% CI 262 
0.65,0.95, respectively, per 10 ng/mL increase in 25(OH)D). Whether differences in 263 
preformed vitamin A intake from supplements modify risk estimates for cause-specific 264 
mortality could not be assessed due to the low number of cases in the supplementation 265 
group. 266 
 267 
DISCUSSION 268 
In this nationally representative sample of US adults, we observed an inverse association of 269 
serum 25(OH)D with all-cause mortality, CVD mortality and mortality due to non-270 
cancer/non-CVD causes. We found these associations to be modified by circulating 271 
concentrations of serum retinyl ester, a commonly used biomarker of possible vitamin A 272 
excess, in a way that the beneficial associations were attenuated among those with 273 
excessively high concentrations (η͹ μg/dL). In addition, high preformed vitamin A intake 274 
(>5000 IU) from supplements was found to diminish the inverse association of 25(OH)D 275 
with overall mortality. However, there was limited statistical evidence of an interaction 276 
between 25(OH)D and vitamin A exposure. 277 
Our results on the relation of serum 25(OH)D and mortality corroborate earlier findings. A 278 
recently published patient level meta-analysis of eight observational studies from Europe 279 
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and the United States, including the NHANES III survey, has shown that low 25(OH)D is 280 
associated with an increase in all-cause and cardiovascular mortality, with a curvilinear 281 
inverse association between 25(OH)D concentration and mortality outcomes [31]. These 282 
results are similar to previous study level meta-analyses of observational studies, where 283 
vitamin D deficiency has been suggested as an independent risk factor for all-cause and CVD 284 
mortality [32-34,8,35]. While the association between serum 25(OH)D and CVD mortality 285 
appears to be a strong inverse association, findings regarding cancer mortality are 286 
heterogeneous. Most prospective studies and meta-analyses have focused on colorectal, 287 
breast, and prostate cancer and often yielded different results depending on tumour type 288 
[36-43]. Schottker et al. [31] observed an association only among subjects with a history of 289 
cancer, and two other recently published meta-analyses showed weak, albeit statistically 290 
significant, elevated pooled risk ratios [10,44]. Studies using data of NHANES III have 291 
reported an inverse association between circulating concentrations of 25(OH)D and overall 292 
[45] as well as cardiovascular disease mortality [46], but the associations with cancer 293 
mortality were not entirely clear [47]. These studies differed from our study in that the 294 
length of follow-up was shorter (7.3 years [46] and 8.7 years [45]) and one study [46] only 295 
included participants aged 65 or older. 296 
We further observed that the inverse associations between 25(OH)D and mortality were 297 
diminished among those with excess circulating retinyl esters. The fact that this pattern did 298 
not hold for serum retinol strata does not conflict with other reports that suggest that 299 
retinol concentrations are under tight homeostatic control and may remain constant or 300 
decline to compensate for higher retinyl ester concentrations [29,48]. The large differences 301 
in risk estimates we observed between strata of vitamin A variables did mostly not result in 302 
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a significant vitamin D-vitamin A interaction, which may be attributed to small case 303 
numbers in the respective subgroups. Previous evidence as to whether vitamin A modifies 304 
vitamin Dǯs effect on mortality is limited. To our knowledge, this is the first study to 305 
examine a possible vitamin D-vitamin A interaction not only in association with cancer 306 
mortality, but also with overall, CVD, and non-cancer/non-CVD mortality. Among the few 307 
epidemiological studies investigating the influence of vitamin A on vitamin D-related cancer 308 
risks, high intakes of retinol were found to mask a beneficial association of vitamin D with 309 
colorectal and pancreatic cancer [22,21]. Several studies on lung cancer have recently been 310 
published but results are conflicting. Cheng, Neuhouser [19] reported that the inverse 311 
association of 25(OH)D with lung cancer mortality seen in non-smokers was more likely to 312 
be observed among those with no sign of excess vitamin A exposure in NHANES III. 313 
Similarly, a recent study in postmenopausal women reported suggestive evidence that 314 
lower vitamin A intake may be important for a beneficial association of vitamin D 315 
supplementation with lung cancer risk [20]. However, statistical evidence to support effect 316 
modification by vitamin A was limited in both studies. In the Alpha-Tocopherol, Beta-317 
Carotene Cancer Prevention Study (ATBC) serum retinol was not found to modify the effect 318 
of vitamin D on lung cancer risk [49] and results of the Carotene and Retinol Efficacy Trial 319 
(CARET) showed that high-dose vitamin A may be important for the protective effect of 320 
vitamin D against lung cancer among smokers [50]. Caution should be exercised when 321 
comparing our results to these findings. In most studies the primary outcome was cancer 322 
incidence rather than mortality. In addition, no study but one [19] used retinyl ester as 323 
biomarker of vitamin A excess and studies on vitamin A intake usually included pro-vitamin 324 
A carotenoids.  325 
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Overall, serum 25(OH)D was similarly inversely associated with all-cause and cause-326 
specific mortality when we stratified analyses by sex. Other studies that reported their 327 
results for all-cause mortality stratified by sex have found very similar results for both 328 
sexes [51,52], stronger associations in men [53], or stronger associations in women [45]. 329 
One study reported a difference between sexes for cause-specific death [54]. Interestingly, 330 
we found the amount of supplemental preformed vitamin A intake to significantly modify 331 
the effect of vitamin D on all-cause mortality. Low case numbers among supplement users 332 
did not allow for gender-specific analyses for cause-specific mortality. 333 
Although we cannot exclude that vitamin D interferes with vitamin A metabolism rather 334 
than the other way around, the biological mechanism by which circulating vitamin A is 335 
thought to mask a beneficial association of 25(OH)D with mortality seems plausible and has 336 
frequently been discussed in the literature [17,55,18]. It involves excessively high 337 
concentrations of 9-cis-retinoic acid, an active metabolite of vitamin A, leading to retinoid X 338 
receptor (RXR) homodimers (RXR-RXR) instead of VDR-RXR heterodimers. Serum 339 
concentrations of 9-cis-retinoic acid are directly related to dietary vitamin A intake [56],  340 
but the precise concentration of vitamin A leading to disturbance of heterodimerisation 341 
remains unknown. In most developed countries including the U.S., consumption of 342 
multivitamin or single supplement products commonly consisting of high-dose preformed 343 
vitamin A has increased over time and concerns of subclinical vitamin A toxicity have 344 
already been raised [57-59]. In our cohort, 21% of study participants took supplements 345 
containing preformed vitamin A and more than 20% had excess circulating vitamin A, 346 defined as retinyl esters η͹.Ͳ μg/dL. 347 
 17 
The strengths of our study include statistical adjustment for a wide range of factors. 348 
Furthermore, NHANES III is a large well-characterized survey, which incorporates a 349 
representative sample of the U.S. population. A number of limitations should be considered 350 
when interpreting our results. First, serum 25(OH)D was only measured once in NHANES 351 
III. Second, serum 25(OH)D data from NHANES III have an inherent season-latitude 352 
structure that prevents assessing associations in specific subgroups. In addition, results of 353 
sub-analyses should be interpreted with caution because of low number of cases. Moreover, 354 
adequate concentrations of vitamin D may reflect a pattern of behavior to minimize threats 355 to oneǯs health and thus be a proxy for a healthy lifestyle. Although we controlled for 356 
numerous confounders, potential residual and unmeasured confounding remains a distinct 357 
possibility.  358 
In this study, inverse associations of 25(OH)D with overall, CVD and non-cancer/non-CVD 359 
mortality were found to be diminished if circulating vitamin A was excessively high (retinyl 360 
esters η͹.Ͳ μg/dL). The beneficial association between 25(OH)D and all-cause mortality 361 
further remained statistically significant only in participants taking preformed vitamin A 362 
from supplements in amounts ζͷͲͲͲ )U. If the interaction effect is real, i.e. vitamin A 363 
interferes with the action of vitamin D, our findings underscore the need to assess safety of 364 
high intakes of preformed vitamin A in order to prevent toxic levels in the body that 365 
potentially undermine a protective effect of vitamin D. Other than with preformed vitamin 366 
A intake, a diet rich in red and yellow-orange fruits and vegetables such as carrots and 367 
sweet potatoes would supply all the carotenoids the body needs to make retinol without the 368 
potential for hypervitaminosis A. Further well-designed studies to more clearly identify a 369 
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potential causal relationship of vitamin D with overall and cause-specific mortality as well 370 
as a potential interaction with vitamin A are warranted. 371 
 372 
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TABLE 1 
     Baseline demographic and health-related characteristics of study participants by quartiles of serum 25-hydroxyvitamin D (25(OH)D) 
    25(OH)D quartiles 
Total Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Vitamin D (ng/mL) <17.7 17.7-24.2 24.3-32.0 >32.0 
Vitamin D (nmol/L)   <44.2 44.2-60.4 60.5-79.9 >79.9 
n 15998 4024 3984 3994 3996 
Follow-up time (y, median) 14.5 14.3 14.5 14.7 14.4 
Age (y) 43.4±16.51 45.0±21.2 45.8±18.5 44.1±16.0 40.9±13.0 
Female (%) 51.2 66.5 56.5 49.6 43.1 
Race/ethnicity (%) 
   Non-Hispanic white 76.5 46.5 67.4 81.2 90.4 
   Non-Hispanic black 10.6 33.8 14.3 6.1 2.3 
   Mexican American 5.1 7.3 7.0 5.4 2.8 
   Other 7.9 12.4 11.4 7.3 4.4 
Season of blood collection (%) 
   Winter/lower latitude 31.5 45.9 35.3 30.3 24.3 
   Summer/higher latitude 68.5 54.1 64.7 69.7 75.7 
Body mass index (kg/m2) 26.4±5.3 27.9±8.0 27.5±6.3 26.3±4.8 25.2±3.6 
Moderate physical activity per week (%) 
   ≤3 39.1 40.6 43.1 39.9 35.7 
   >3 46.5 32.8 39.1 46.6 56.1 
   Never 14.4 26.6 17.8 13.5 8.2 
Poverty-income ratio (%) 
   Poor 17.5 25.1 19.6 16.4 14.0 
   Middle income 42.7 41.9 43.4 40.7 44.2 
   Higher income 33.5 26.6 30.2 36.7 35.8 
   Missing 6.3 6.4 6.9 6.2 6.0 
Education (%) 
   Less than high school 26.4 29.3 28.2 27.0 23.9 
   High school 33.5 37.2 33.8 31.1 33.5 
   More than high school 40.1 33.4 38.0 41.9 42.7 
Smoking status (%) 
   Current, ≤20 cigarettes/day 19.9 25.3 19.5 18.0 19.2 
   Current, >20 cigarettes/day 7.3 6.0 6.2 7.2 8.5 
 24 
   Former 25.3 20.5 24.2 25.8 27.5 
   Never 47.5 48.1 50.0 49.1 44.8 
Alcohol consumption per week (%) 
   ≤2  26.3 25.4 25.6 26.7 26.8 
   >2 28.6 21.7 23.7 30.8 32.5 
   Never 45.1 52.9 50.6 42.6 40.7 
Diabetes mellitus (%) 5.2 8.5 6.3 5.5 3.0 
Hypertension (%) 18.7 23.1 21.3 18.5 15.6 
Hypercholesterolemia (%) 19.5 19.0 20.9 19.1 19.1 
Chronic obstructive pulmonary disease (%) 13.0 16.2 13.3 13.1 11.4 
History of cancer (%) 3.5 3.1 4.0 3.7 3.3 
History of stroke (%) 1.9 2.8 2.3 1.6 1.5 
Histry of myocardial infarction (%) 3.3 3.9 4.0 3.2 2.8 
1Mean±SD (all such variables) 
All estimates were weighted to account for the complex survey design of NHANES III 
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TABLE 2 
    Hazard ratios with 95% confidence intervals for all-cause and cause-specific mortality in NHANES III (1988–2006)1 
Continuous model2 All-cause Cancer CVD Non-cancer-non-CVD 
ncases 3890 871 1715 1284 
   Model 1 0.89 (0.85,0.94) 0.98 (0.87,1.09) 0.87 (0.81,0.93) 0.87 (0.79,0.95) 
   Model 2 0.93 (0.88,0.97) 1.01 (0.90,1.13) 0.91 (0.85,0.98) 0.88 (0.81,0.97) 
   Model 3 0.93 (0.89,0.97) 1.01 (0.90,1.13) 0.92 (0.86,0.98) 0.89 (0.82,0.97) 
      Serum retinyl esters     
 
  
         ncases 963 175 413 312 
         ≥7.0 μg/dL 0.97 (0.85,1.09) 0.94 (0.73,1.21) 0.98 (0.86,1.10) 0.98 (0.83,1.16) 
         ncases 2927 669 1249 972 
         <7.0 μg/dL 0.92 (0.88,0.97) 1.04 (0.93, 1.17) 0.90 (0.82,0.98) 0.87 (0.78,0.96) 
      Serum retinol         
         ncases 1269 240 609 413 
         Above 75th percentile (> 69 μg/dL) 0.89 (0.82,0.96) 0.94 (0.75,1.16) 0.88 (0.78,0.99) 0.86 (0.75,0.98) 
         ncases 2621 604 1106 871 
         At or below 75th percentile (≤ 69 μg/dL) 0.95 (0.90,1.01) 1.05 (0.89,1.24) 0.94 (0.86,1.03) 0.90 (0.81,0.99) 
      Preformed vitamin A supplement use         
         ncases 838 187 363 281 
         Yes 0.89 (0.79,1.00) 0.93 (0.71,1.21) 0.97 (0.84,1.11) 0.79 (0.65,0.95) 
         ncases 3052 657 1352 1003 
         No 0.95 (0.89,1.01) 1.04 (0.90,1.19) 0.91 (0.83,0.99) 0.93 (0.84,1.04) 
      Preformed vitamin A intake from supplements         
         ncases 81 
   
         Above 75th percentile  (> 5000IU) 1.01 (0.72,1.43) 
   
         ncases 757 
   
         At or below 75th percentile (≤ 5000IU) 0.87 (0.77,0.97) 
   
1ncases, number of deaths; Model 1 was adjusted for age, sex, race/ethnicity, and season; Model 2 was adjusted for variables of model 1 and for 
lifestyle and socioeconomic factors (poverty-income ratio, body mass index, physical activity, smoking status, alcohol consumption, education and 
hormone replacement therapy); Model 3 was adjusted for variables of model 2 and for potential intermediates (hypertension, diabetes mellitus, 
hypercholesterolemia, history of myocardial infarction, history of stroke, and history of cancer; All P-values for interaction were >0.05 
2Per 10 ng/mL increase in 25(OH)D entered as a continuous variable 
All estimates were weighted to account for the complex survey design of NHANES III 
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SUPPLEMENTARY TABLE 1 
      Sex-specific hazard ratios with 95% confidence intervals for all-cause mortality by quartiles of serum 25-hydroxyvitamin D [25(OH)D] in NHANES III (1988–2006)1 
Hazard ratios (95% CI) by quartiles of 25(OH)D (ng/mL) 
  
Quartile 1 (<17.7) Quartile 2 (17.7-24.2) 
Quartile 3 (24.3-
32.0) Quartile 4 (>32.0) continuous model2 P-interaction 
Men           
 ncases 408 514 578 602 
 
   Model 1 1.00 (reference) 0.83 (0.68,1.01) 0.73 (0.58,0.92) 0.75 (0.61,0.93) 0.95 (0.89, 1.02) 
 
   Model 2 1.00 (reference) 0.88 (0.73,1.07) 0.80 (0.65,1.00) 0.78 (0.64,0.95) 0.95 (0.89,1.01) 
 
   Model 3 1.00 (reference) 0.89 (0.73,1.08) 0.79 (0.64,0.97) 0.81 (0.67,0.98) 0.95 (0.89,1.01) 
 
      Serum retinyl esters 
    
 
pcat=0.71, pcont=0.19 
         ncases 51 102 128 163 
 
         ≥7.0 μg/dL 1.00 (reference) 0.92 (0.51,1.65) 0.86 (0.45,1.68) 0.94 (0.50,1.78) 1.05 (0.89,1.23) 
 
         ncases 357 412 450 439 
 
         <7.0 μg/dL 1.00 (reference) 0.90 (0.71,1.13) 0.76 (0.59,1.00) 0.78 (0.63,0.95) 0.93 (0.87,0.99) 
 
      Serum retinol 
    
pcat=0.29, pcont=0.29 
         ncases 101 171 199 248 
         Above 75th percentile (> 69 μg/dL) 1.00 (reference) 0.66 (0.43,1.02) 0.62 (0.41,0.95) 0.60 (0.38,0.95) 0.91 (0.81,1.02) 
 
         ncases 307 343 379 354 
 
         At or below 75th percentile (≤ 69 μg/dL) 1.00 (reference) 1.01 (0.83,1.21) 0.83 (0.66,1.05) 0.89 (0.72,1.11) 0.98 (0.90,1.06) 
 
      Preformed vitamin A supplement use 
    
pcat=0.21, pcont=0.16 
         ncases 39 89 116 154 
         Yes 1.00 (reference) 0.75 (0.47,1.22)  0.56 (0.33,0.95) 0.57 (0.35,0.94) 0.85 (0.72,1.00) 
         ncases 369 425 462 448 
         No 1.00 (reference) 0.90 (0.73,1.10) 0.87 (0.71,1.06) 0.85 (0.70,1.03) 0.98 (0.91,1.05) 
      Preformed vitamin A intake from supplements 
    
pcat=0.04, pcont=0.06 
         ncases 3 11 10 20 
         Above 75th percentile  (> 5000IU) 1.00 (reference) 3.10 (0.34,28.51) 1.15 (0.15,8.67) 4.93 (0.80,30.40) 1.64 (0.89,3.01) 
 
         ncases 36 78 106 134 
 
         At or below 75th percentile (≤ 5000IU) 1.00 (reference) 0.64  (0.40,1.03) 0.48  (0.27,0.84) 0.47  (0.29,0.76) 0.80 (0.70,0.92) 
 Women           
 ncases 582 478 411 317 
 
   Model 1 1.00 (reference) 0.75 (0.64,0.87) 0.67 (0.55,0.81) 0.58 (0.48,0.71) 0.84 (0.77,0.91) 
 
   Model 2 1.00 (reference) 0.84 (0.73,0.96) 0.81 (0.68,0.97) 0.73 (0.60,0.88) 0.91 (0.85,0.99) 
 
   Model 3 1.00 (reference) 0.88 (0.77,1.01) 0.82 (0.69,0.97) 0.77 (0.63,0.95) 0.92 (0.86,1.00) 
 
      Serum retinyl esters 
    
 
pcat=0.91, pcont=0.64 
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         ncases 98 161 133 127 
 
         ≥7.0 μg/dL 1.00 (reference) 0.80 (0.52,1.21) 0.71 (0.47,1.07) 0.72 (0.42,1.25) 0.92 (0.76,1.12) 
 
         ncases 484 317 278 190 
 
         <7.0 μg/dL 1.00 (reference) 0.88 (0.74,1.04) 0.82 (0.65,1.03) 0.80 (0.59,1.07) 0.93 (0.84,1.02) 
 
      Serum retinol 
 
pcat=0.10, pcont=0.38 
         ncases 136 144 129 141 
         Above 75th percentile (> 69 μg/dL) 1.00 (reference) 0.95 (0.69,1.31) 0.69 (0.50,0.95) 0.67 (0.45,1.00) 0.87 (0.76,1.00) 
 
         ncases 446 334 282 176 
 
         At or below 75th percentile (≤ 69 μg/dL) 1.00 (reference) 0.84 (0.69,1.02) 0.88 (0.72,1.09) 0.78 (0.60,1.03) 0.93 (0.84,1.02) 
 
      Preformed vitamin A supplement use 
    
pcat=0.14, pcont=0.97 
         ncases 72 111 125 132 
         Yes 1.00 (reference) 0.76 (0.46,1.25) 0.59 (0.41,0.85) 0.66 (0.40,1.09) 0.93 (0.76,1.13) 
         ncases 510 367 286 185 
         No 1.00 (reference) 0.91 (0.77,1.08)  0.90 (0.72,1.14) 0.77 (0.60,0.99) 0.92 (0.83,1.02) 
      Preformed vitamin A intake from supplements 
    
pcat=0.50, pcont=0.16 
         ncases 3 6 6 22 
         Above 75th percentile  (> 5000IU) 1.00 (reference) 0.26 (0.05,1.41) 0.08 (0.00,5.15) 0.69 (0.19,2.57) 0.80 (0.49,1.31) 
 
         ncases 69 105 119 110 
 
         At or below 75th percentile (≤ 5000IU) 1.00 (reference) 0.75 (0.46,1.21) 0.63 (0.43,0.92) 0.68 (0.43,1.09) 0.95 (0.77,1.16)   
1ncases, number of deaths; pcat, P-value of test for interaction in the categorical model; pcont, P-value of test for interaction in the continuous model; Model 1 was adjusted for age, 
sex, race/ethnicity, and season; Model 2 was adjusted for variables of model 1 and for lifestyle and socioeconomic factors (poverty-income ratio, body mass index, physical 
activity, smoking status, alcohol consumption, education and hormone replacement therapy); Model 3 was adjusted for variables of model 2 and for potential intermediates 
(hypertension, diabetes mellitus, hypercholesterolemia, history of myocardial infarction, history  of stroke, and history of cancer 
2Per 10 ng/mL increase in 25(OH)D entered as a continuous variable 
All estimates were weighted to account for the complex survey design of NHANES III  
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SUPPLEMENTARY TABLE 2 
     Hazard ratios with 95% confidence intervals for all-cause and cause-specific mortality by quartiles of serum 25-hydroxyvitamin D [25(OH)D] in NHANES III (1988–2006)1 
Hazard ratios (95% CI) by quartiles of 25(OH)D (ng/mL) 
  
Quartile 1 (<17.7) Quartile 2 (17.7-24.2) Quartile 3 (24.3-32.0) Quartile 4 (>32.0) continuous model2 
All-cause           
ncases 990 992 989 919 
   Model 1 1.00 (reference) 0.78 (0.68,0.88) 0.68 (0.59,0.79) 0.66 (0.58,0.75) 0.89 (0.85,0.94) 
   Model 2 1.00 (reference) 0.84 (0.75,0.94) 0.78 (0.69,0.89) 0.74 (0.65,0.83) 0.93 (0.88,0.97) 
   Model 3 1.00 (reference) 0.87 (0.77,0.97) 0.78 (0.69,0.89) 0.77 (0.68,0.87) 0.93 (0.89,0.97) 
      Serum retinyl esters           
         ncases 149 263 261 290 
 
         ≥7.0 μg/dL 1.00 (reference) 0.85 (0.59,1.23) 0.75 (0.52,1.10) 0.79 (0.53,1.20) 0.97 (0.85,1.09) 
         ncases 841 729 728 629 
         <7.0 μg/dL 1.00 (reference) 0.87 (0.77,1.00) 0.78 (0.65,0.92) 0.77 (0.67,0.88) 0.92 (0.88,0.97) 
      Serum retinol           
         ncases 237 315 328 389 
         Above 75th percentile (> 69 μg/dL) 1.00 (reference) 0.82 (0.64,1.06) 0.66 (0.52,0.84) 0.64 (0.48,0.86) 0.89 (0.82,0.96) 
         ncases 753 677 661 530 
         At or below 75th percentile (≤ 69 μg/dL) 1.00 (reference) 0.88 (0.77,1.00) 0.82 (0.71,0.94) 0.82 (0.71,0.96) 0.95 (0.90,1.01) 
      Preformed vitamin A supplement use           
         ncases 111 200 241 286 
         Yes 1.00 (reference) 0.76 (0.52,1.12) 0.58 (0.42,0.81) 0.63 (0.43,0.92) 0.89 (0.79,1.00) 
         ncases 879 792 748 633 
         No 1.00 (reference) 0.89 (0.79,1.00) 0.86 (0.74,1.00) 0.80 (0.68,0.94) 0.95 (0.89,1.01) 
      Preformed vitamin A intake from supplements           
         ncases 6 17 16 42 
         Above 75th percentile  (> 5000IU) 1.00 (reference) 0.86 (0.27,2.75) 0.44 (0.11,1.73) 1.13 (0.48,2.68) 1.01 (0.72,1.43) 
         ncases 105 183 225 244 
         At or below 75th percentile (≤ 5000IU) 1.00 (reference) 0.73 (0.51,1.04) 0.57 (0.41,0.80) 0.59 (0.41,0.85) 0.87 (0.77,0.97) 
Cancer           
ncases 201 218 214 211 
   Model 1 1.00 (reference) 0.91 (0.69,1.20) 0.83 (0.63,1.10) 0.80 (0.61,1.05) 0.98 (0.87,1.09) 
   Model 2 1.00 (reference) 1.00 (0.75,1.32) 0.98 (0.73,1.32) 0.92 (0.67,1.25) 1.01 (0.90,1.13) 
   Model 3 1.00 (reference) 0.99 (0.74,1.32) 0.93 (0.68,1.27) 0.92 (0.66,1.28) 1.01 (0.90,1.13) 
      Serum retinyl esters           
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         ncases 22 46 52 55 
         ≥7.0 μg/dL 1.00 (reference) 0.81 (0.36,1.86) 0.80 (0.33,1.97) 0.65 (0.25,1.67) 0.94 (0.73,1.21) 
         ncases 179 172 162 156 
         <7.0 μg/dL 1.00 (reference) 1.05 (0.80,1.37) 0.92 (0.69,1.24) 1.04 (0.77,1.42) 1.04 (0.93, 1.17) 
      Serum retinol           
         ncases 42 60 62 76 
         Above 75th percentile (> 69 μg/dL) 1.00 (reference) 0.84 (0.44,1.61) 0.77 (0.45,1.32) 0.72 (0.36,1.42) 0.94 (0.75,1.16) 
         ncases 159 158 152 135 
         At or below 75th percentile (≤ 69 μg/dL) 1.00 (reference) 1.06 (0.76,1.48) 0.99 (0.67,1.44) 1.01 (0.68,1.49) 1.05 (0.89,1.24) 
      Preformed vitamin A supplement use           
         ncases 26 46 52 63 
         Yes 1.00 (reference) 0.90 (0.35,2.30) 0.67 (0.27,1.62) 0.73 (0.28,1.94) 0.93 (0.71,1.21) 
         ncases 175 172 162 148 
         No 1.00 (reference) 0.97 (0.72,1.30) 1.01 (0.73,1.39) 0.94 (0.67,1.32) 1.04 (0.90,1.19) 
Cardiovascular disease           
ncases 449 433 430 403 
   Model 1 1.00 (reference) 0.75 (0.64,0.88) 0.63 (0.54,0.75) 0.65 (0.55,0.77) 0.87 (0.81,0.93) 
   Model 2 1.00 (reference) 0.80 (0.68,0.95) 0.72 (0.61,0.85) 0.74 (0.63,0.88) 0.91 (0.85,0.98) 
   Model 3 1.00 (reference) 0.84 (0.71,1.00) 0.74 (0.63,0.86) 0.79 (0.67,0.94) 0.92 (0.86,0.98) 
      Serum retinyl esters           
         ncases 79 127 121 139 
         ≥7.0 μg/dL 1.00 (reference) 0.84 (0.56,1.26) 0.73 (0.47,1.14) 0.87 (0.59,1.30) 0.98 (0.86,1.10) 
         ncases 370 306 309 264 
         <7.0 μg/dL 1.00 (reference) 0.84 (0.68,1.04) 0.72 (0.57,0.91) 0.76 (0.61,0.95) 0.90 (0.82,0.98) 
      Serum retinol           
         ncases 118 153 154 184 
         Above 75th percentile (> 69 μg/dL) 1.00 (reference) 0.85 (0.59,1.22) 0.58 (0.41,0.81) 0.62 (0.44,0.89) 0.88 (0.78,0.99) 
         ncases 331 280 276 219 
         At or below 75th percentile (≤ 69 μg/dL) 1.00 (reference) 0.82 (0.66,1.01) 0.83 (0.68,1.01) 0.91 (0.69,1.20) 0.94 (0.86,1.03) 
      Preformed vitamin A supplement use           
         ncases 50 84 104 125 
         Yes 1.00 (reference) 0.63 (0.39,1.03) 0.55 (0.34,0.90) 0.71 (0.41,1.24) 0.97 (0.84,1.11) 
         ncases 399 349 326 278 
         No 1.00 (reference) 0.92 (0.76,1.12) 0.82 (0.67,1.01) 0.81 (0.64,1.02) 0.91 (0.83,0.99) 
Non-cancer-non-cardiovascular disease           
ncases 328 330 331 295 
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   Model 1 1.00 (reference) 0.73 (0.58,0.93) 0.65 (0.49,0.86) 0.59 (0.43,0.80) 0.87 (0.79,0.95) 
   Model 2 1.00 (reference) 0.80 (0.63,1.01) 0.74 (0.56,0.97) 0.63 (0.47,0.84) 0.88 (0.81,0.97) 
   Model 3 1.00 (reference) 0.82 (0.65,1.04) 0.74 (0.57,0.97) 0.67 (0.51,0.88) 0.89 (0.82,0.97) 
      Serum retinyl esters           
         ncases 47 89 84 92 
         ≥7.0 μg/dL 1.00 (reference) 0.90 (0.53,1.55) 0.70 (0.40,1.21) 0.81 (0.42,1.55) 0.98 (0.83,1.16) 
         ncases 281 241 247 203 
         <7.0 μg/dL 1.00 (reference) 0.81 (0.62,1.05) 0.76 (0.55,1.03) 0.64 (0.47,0.86) 0.87 (0.78,0.96) 
      Serum retinol           
         ncases 76 100 110 127 
         Above 75th percentile (> 69 μg/dL) 1.00 (reference) 0.79 (0.48,1.30) 0.70 (0.45,1.09) 0.63 (0.35,1.11) 0.86 (0.75,0.98) 
         ncases 252 230 221 168 
         At or below 75th percentile (≤ 69 μg/dL) 1.00 (reference) 0.83 (0.64,1.07) 0.72 (0.54,0.97) 0.65 (0.51,0.84) 0.90 (0.81,0.99) 
      Preformed vitamin A supplement use           
         ncases 34 67 82 98 
         Yes 1.00 (reference) 0.85 (0.53,1.36) 0.55 (0.33,0.92) 0.52 (0.30,0.89) 0.79 (0.65,0.95) 
         ncases 294 263 249 197 
         No 1.00 (reference) 0.79 (0.61,1.03) 0.81 (0.60,1.08) 0.71 (0.52,0.97) 0.93 (0.84,1.04) 
1ncases, number of deaths; Model 1 was adjusted for age, sex, race/ethnicity, and season; Model 2 was adjusted for variables of model 1 and for lifestyle and socioeconomic 
factors (poverty-income ratio, body mass index, physical activity, smoking status, alcohol consumption, education and hormone replacement therapy); Model 3 was 
adjusted for variables of model 2 and for potential intermediates (hypertension, diabetes mellitus, hypercholesterolemia, history of myocardial infarction, history  of stroke, 
and history of cancer; All P-values for interaction were >0.05 
2Per 10 ng/mL increase in 25(OH)D entered as a continuous variable 
All estimates were weighted to account for the complex survey design of NHANES III 
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FIGURE 1 
Association between circulating 25(OH)D concentration and all-cause mortality by vitamin A markers in NHANES III (1988–2006); Results are reported as hazard 
ratios with 95% confidence intervals (CI) per 10 ng/mL increase of 25(OH)D concentration (horizontal bar), adjusted for all variables in model 31 
 
(Figure 1 from jpg/png file: Fig1.jpg or Fig 1.png. MS Excel was used to create figure 1.) 
 
1Model 3 was adjusted for age, sex, race/ethnicity, and season, lifestyle and socioeconomic factors (poverty-income ratio, body mass index, physical activity, 
smoking status, alcohol consumption, education and hormone replacement therapy) and for potential intermediates (hypertension, diabetes mellitus, 
hypercholesterolemia, history of myocardial infarction, history of stroke, and history of cancer). All estimates were weighted to account for the complex survey 
design of NHANES III 
 

